William Workman, DO
Internal Medicine · Battle Creek, MINPI 1407110257
Payments from drug & device makers
Across 198 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$903
- Si-bone, Inc.$403
- Xeris Pharmaceuticals, Inc.$377
- Pfizer$347
- Biohaven Pharmaceutical Holding Company Ltd.$120
- Amarin Pharma, Inc.$117
- plus $1K from 28 others
What the payments were for
- Travel & lodging$40311%
- Food & beverage$3,21588%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $903 |
| Si-bone, Inc. | 2 | $403 |
| Xeris Pharmaceuticals, Inc. | 21 | $377 |
| Pfizer | 31 | $347 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $120 |
| Amarin Pharma, Inc. | 7 | $117 |
| Amgen | 7 | $112 |
| Novartis | 5 | $95 |
| Johnson & Johnson | 6 | $91 |
| Merck | 5 | $91 |
| AbbVie | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $79 |
| Lilly USA, LLC | 5 | $79 |
| Daiichi Sankyo Inc. | 4 | $74 |
| Abbott | 4 | $74 |
| Dexcom, Inc. | 4 | $69 |
| AstraZeneca(2 entities) | 4 | $67 |
| Biohaven Pharmaceuticals, Inc. | 3 | $62 |
| Astellas Pharma US Inc | 1 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Sanofi Pasteur Inc. | 2 | $51 |
| Lundbeck LLC | 2 | $40 |
| Mylan Specialty L.p. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $20 |
| Medtronic | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Dynavax Technologies Corporation | 2 | $18 |
| Insulet Corporation | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Exact Sciences | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,673 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $209,940 |
| OzempicSemaglutide | 102 | $163,943 |
| MounjaroTirzepatide | 93 | $108,360 |
| TrulicityDulaglutide | 65 | $101,455 |
| XareltoRivaroxaban | 67 | $95,540 |
| JardianceEmpagliflozin | 56 | $73,997 |
| Repatha SureclickEvolocumab | 87 | $63,673 |
| LinzessLinaclotide | 40 | $41,459 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $37,706 |
| RybelsusSemaglutide | 14 | $34,751 |
| JanuviaSitagliptin Phosphate | 25 | $32,302 |
| MyrbetriqMirabegron | 45 | $26,658 |
| EntrestoSacubitril/Valsartan | 20 | $24,692 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $24,311 |
| FarxigaDapagliflozin Propanediol | 17 | $20,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Premarin | $347 | $235,252195 claims |
| Lilly USA, LLCMounjaro, Trulicity | $79 | $209,815158 claims |
| Novo NordiskOzempic, Rybelsus | $903 | $198,695116 claims |
| Johnson & JohnsonXarelto | $91 | $95,54067 claims |
| Boehringer IngelheimJardiance | $13 | $73,99756 claims |
| AbbVieLinzess, Synthroid | $90 | $47,160120 claims |
| AstraZenecaFarxiga, Nexium, Symbicort | $67 | $35,75147 claims |
| MerckJanuvia | $91 | $32,30225 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $26,65845 claims |
| NovartisEntresto | $95 | $24,69220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Battle Creek
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.